Oral Beraprost Sodium, a Prostaglandin I 2 Analogue, for Intermittent Claudication
- 25 July 2000
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 102 (4), 426-431
- https://doi.org/10.1161/01.cir.102.4.426
Abstract
Background —Beraprost sodium (BPS) is a new stable, orally active prostaglandin I 2 analogue with antiplatelet and vasodilating properties. We report the results of a phase III clinical trial of BPS in patients with intermittent claudication. Methods and Results —Patients (n=549) with a pain-free walking distance of between 50 and 300 m were entered into a 4-week single-blind placebo run-in phase. Patients whose pain-free walking distance had changed by 50% in pain-free walking distance at month 6 and in ≥1 earlier treadmill exercise test in the absence of critical cardiovascular events. Success was observed more frequently in the BPS group (43.5%) than in the placebo group (33.3%, P =0.036). Pain-free walking distances increased by 81.5% and 52.5%, respectively, in the BPS and placebo groups ( P =0.001) and maximum walking distances by 60.1% and 35.0%, respectively ( P =0.004). The incidence of critical cardiovascular events was 4.8% in the BPS group and 8.9% in the placebo group. Conclusions —These results show that BPS is an effective symptomatic treatment of patients with intermittent claudication. The beneficial effects of BPS on critical cardiovascular events should be confirmed in appropriate clinical trials.Keywords
This publication has 15 references indexed in Scilit:
- Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: Results of a multicenter placebo-controlled double-blind trialJournal of Vascular Surgery, 1997
- Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjectsCanadian Journal of Physiology and Pharmacology, 1996
- A Dose-Effect Study of Beraprost Sodium in Intermittent ClaudicationJournal of Cardiovascular Pharmacology, 1996
- Pharmacokinetics and Platelet Antiaggregating Effects of Beraprost, an Oral Stable Prostacyclin Analogue, in Healthy VolunteersJournal of Cardiovascular Pharmacology, 1993
- Quality of life assessment in therapeutic trials: rationale for and presentation of a more appropriate instrumentFundamental & Clinical Pharmacology, 1992
- IloprostDrugs, 1992
- Edinburgh Artery Study: Prevalence of Asymptomatic and Symptomatic Peripheral Arterial Disease in the General PopulationInternational Journal of Epidemiology, 1991
- A double blind placebo controlled trial of intravenous prostacyclin (PGI2) in 108 patients with ischaemic peripheral vascular diseaseProstaglandins, 1990
- Phase i study of beraprost sodium (TRK-100), a prostacyclin derivative - Repeated oral administration study for 10 days.Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 1989
- Epidemiology of atherosclerotic arterial disease in the lower limbsEuropean Journal of Vascular Surgery, 1988